Melanoma News and Research

Latest Melanoma News and Research

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

29 Sep 2014

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

BRD4 protein appears to play key role in keeping stem cells in immature "pluripotent" state

A protein implicated in several cancers appears to play a pivotal role in keeping stem cells in an immature "pluripotent" state, according to a new study by NYU Langone Medical Center scientists.

26 Sep 2014

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.

From EKF Diagnostics 23 Sep 2014

Longer telomeres increase melanoma risk

A leading Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, an international research consortium, co-authored a paper published today in the Journal of the National Cancer Institute that proves longer telomeres increase the risk of melanoma.

21 Sep 2014

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy.

19 Sep 2014

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers.

18 Sep 2014

Photoelectric therapy for non-melanoma skin cancer developed by Xstrahl

With a presence in over 500 clinics around the world, Xstrahl have drawn upon their vast clinical expertise to develop a revolutionary system that has been specifically designed for the treatment superficial skin cancers and skin conditions.

From Xstrahl 18 Sep 2014

New approach to imaging metastatic tumors

Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors.

18 Sep 2014

Study uncovers new genetic risk factor for deadly skin cancer

Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma - the deadliest form of skin cancer - according to new research from the University of Leeds.

18 Sep 2014

Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR [Agence Nationale pour la Recherche].

17 Sep 2014

Soldiers deployed to sunny climates face increased risk of skin cancer

Soldiers deployed to tropical and sunny climates are coming home with increased risk factors for a threat far from the battlefield: skin cancer.

17 Sep 2014

Scientists develop "electronic skin" for earlier identification of breast cancer

For detecting cancer, manual breast exams seem low-tech compared to other methods such as MRI. But scientists are now developing an "electronic skin" that "feels" and images small lumps that fingers can miss.

11 Sep 2014

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.

10 Sep 2014

Study evaluates impact of myPath Melanoma diagnostic test

Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath- Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill.

10 Sep 2014

Ortho-oncology team successfully adapts shoulder surgical aid

An ortho-oncology team at Dartmouth-Hitchcock Norris Cotton Cancer Center successfully adapted a shoulder surgical aid (the Spider Limb Positioner) to conduct a left hip disarticulation on a melanoma patient as described in a case report published online in Medical Devices.

9 Sep 2014

New immuno-oncology drug helps body's own immune system to fend off cancer

According to an August 25 Reuters report, the U.S. Food and Drug Administration is likely to approve Merck & Co.'s highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline.

8 Sep 2014

Melanoma News and Research

Latest Melanoma News and Research

Combination therapy achieves greater progression-free survival, response rates in melanoma

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

BRD4 protein appears to play key role in keeping stem cells in immature "pluripotent" state

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

Longer telomeres increase melanoma risk

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Photoelectric therapy for non-melanoma skin cancer developed by Xstrahl

New approach to imaging metastatic tumors

Study uncovers new genetic risk factor for deadly skin cancer

Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Soldiers deployed to sunny climates face increased risk of skin cancer

Scientists develop "electronic skin" for earlier identification of breast cancer

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

Study evaluates impact of myPath Melanoma diagnostic test

Ortho-oncology team successfully adapts shoulder surgical aid

New immuno-oncology drug helps body's own immune system to fend off cancer

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Melanoma News and Research

Latest Melanoma News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in